Serum Advanced Glycation End-Products and Receptors as Prognostic Biomarkers in Diabetics Undergoing Coronary Artery Stent Implantation

Canadian Journal of Cardiology

Volumn 28, Issue 6, 2012, Pages 737-743

  Shen, Ying ^a   Pu, Li Jin ^a   Lu, Lin ^a   Zhang, Qi ^a   Zhang, Rui Yan ^a   Shen, Wei Feng ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; GLYCOSYLATED ALBUMIN; HEMOGLOBIN A1C; RAPAMYCIN;

ACUTE KIDNEY FAILURE; ADULT; ARTICLE; DISEASE SEVERITY; DRUG ELUTING STENT; FEMALE; FOLLOW UP; HUMAN; MACROALBUMINURIA; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PERCUTANEOUS CORONARY INTERVENTION; TREATMENT OUTCOME;

AGED; BIOLOGICAL MARKERS; CORONARY ARTERY DISEASE; DIABETES MELLITUS, TYPE 2; DRUG-ELUTING STENTS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; GLYCOSYLATION END PRODUCTS, ADVANCED; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MALE; MIDDLE AGED; PERCUTANEOUS CORONARY INTERVENTION; PROGNOSIS; RECEPTORS, IMMUNOLOGIC; RETROSPECTIVE STUDIES;

EID: 84869079833     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2012.08.015     Document Type: Article

References (32)

1. Yamagishi S. Role of advanced glycation end products (AGEs) and receptor for AGEs (RAGE) in vascular damage in diabetes. Exp Gerontol 2011, 46:217-224.
2. Sourris K.C., Forbes J.M. Interactions between advanced glycation end-products (AGE) and their receptors in the development and progression of diabetic nephropathy - are these receptors valid therapeutic targets. Curr Drug Targets 2009, 10:42-50.
3. Lu L., Pu L.J., Xu X.W., et al. Association of serum levels of glycated albumin, C-reactive protein and tumor necrosis factor-alpha with the severity of coronary artery disease and renal impairment in patients with type 2 diabetes mellitus. Clin Biochem 2007, 40:810-816.
4. Barnaby O.S., Cerny R.L., Clarke W., Hage D.S. Comparison of modification sites formed on human serum albumin at various stages of glycation. Clin Chim Acta 2011, 412:277-285.
5. Chen S., Cohen M.P., Ziyadeh F.N. Amadori-glycated albumin in diabetic nephropathy: pathophysiologic connections. Kidney Int Suppl 2000, 77:S40-S44.
6. Cohen M.P., Chen S., Ziyadeh F.N., et al. Evidence linking glycated albumin to altered glomerular nephrin and VEGF expression, proteinuria, and diabetic nephropathy. Kidney Int 2005, 68:1554-1561.
7. Lee B.W., Ihm J., Kang J.G., Choi M.G., Yoo H.J., Ihm S.H. Amadori-glycated albumin-induced vascular smooth muscle cell proliferation and expression of inhibitor of apoptosis protein-1 and nerve growth factor-gamma. Biofactors 2007, 31:145-153.
8. Cohen M.P., Shea E., Chen S., Shearman C.W. Glycated albumin increases oxidative stress, activates NF-kappa B and extracellular signal-regulated kinase (ERK), and stimulates ERK-dependent transforming growth factor-beta 1 production in macrophage RAW cells. J Lab Clin Med 2003, 141:242-249.
9. Hattori Y., Banba N., Gross S.S., Kasai K. Glycated serum albumin-induced nitric oxide production in vascular smooth muscle cells by nuclear factor kappa B-dependent transcriptional activation of inducible nitric oxide synthase. Biochem Biophys Res Commun 1999, 1:128-132.
10. Amore A., Cirina P., Cirina P., et al. Amadori-configurated albumin induces nitric oxide-dependent apoptosis of endothelial cells: a possible mechanism of diabetic vasculopathy. Nephrol Dial Transplant 2004, 19:53-60.
11. Rodiño-Janeiro B.K., González-Peteiro M., Ucieda-Somoza R., González-Juanatey J.R., Alvarez E. Glycated albumin, a precursor of advanced glycation end-products, up-regulates NADPH oxidase and enhances oxidative stress in human endothelial cells: molecular correlate of diabetic vasculopathy. Diabetes Metab Res Rev 2010, 26:550-558.
12. Semba R.D., Ferrucci L., Fink J.C., et al. Advanced glycation end products and their circulating receptors and level of kidney function in older community-dwelling women. Am J Kidney Dis 2009, 53:51-58.
13. Yamagishi S., Matsui T. Soluble form of a receptor for advanced glycation end products (sRAGE) as a biomarker. Front Biosci (Elite Ed) 2010, 2:1184-1195.
14. Lu L., Pu L.J., Zhang Q., et al. Increased glycated albumin and decreased esRAGE levels are related to angiographic severity and extent of coronary artery disease in patients with type 2 diabetes. Atherosclerosis 2009, 206:540-545.
15. Pu L.J., Lu L., Xu X.W., et al. Value of serum glycated albumin and high-sensitivity C-reactive protein levels in the prediction of presence of coronary artery disease in patients with type 2 diabetes. Cardiovasc Diabetol 2006, 5:27.
16. Pu L.J., Lu L., Shen W.F., et al. Increased serum glycated albumin level is associated with the presence and severity of coronary artery disease in type 2 diabetic patients. Circ J 2007, 71:1067-1073.
17. Mattock M.B., Morrish N.J., Verbti G., Fitzgerald A.P., Jackson G. Prospective study of microalbuminuria as predictor of mortality. Diabetes 1992, 42:736-741.
18. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 2003, 26(Suppl 1):S5-S20. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus.
19. Rossi M.C., Nicolucci A., Pellegrini F., et al. Identifying patients with type 2 diabetes at high risk of microalbuminuria: results of the DEMAND (Developing Education on Microalbuminuria for Awareness of renal and cardiovascular risk in Diabetes) Study. Nephrol Dial Transplant 2008, 23:1278-1284.
20. Du R., Zhang R.Y., Zhu Z.B., et al. Impact of angiographic and intravascular ultrasound features on clinical outcome after sirolimus-eluting stent implantation for de-novo lesions in nondiabetic and type 2 diabetic patients. Coron Artery Dis 2010, 21:175-181.
21. Levey A.S., Bosch J.P., Lewis J.B., Greene T., Rogers N., Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999, 130:461-470.
22. McCullough P.A. Contrast-induced acute kidney injury. J Am Coll Cardiol 2008, 51:1419-1428.
23. Yokoyama H., Sone H., Oishi M., et al. Prevalence of albuminuria and renal insufficiency and associated clinical factors in type 2 diabetes: the Japan Diabetes Clinical Data Management study (JDDM15). Nephrol Dial Transplant 2009, 24:1212-1219.
24. Wa C., Cerny R.L., Clarke W.A., Hage D.S. Characterization of glycation adducts on human serum albumin by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Clin Chim Acta 2007, 385:48-60.
25. Selvin E., Francis L.M., Ballantyne C.M., et al. Nontraditional markers of glycemia: associations with microvascular conditions. Diabetes Care 2011, 34:960-967.
26. Raucci A., Cugusi S., Antonelli A., et al. A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membrane-bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10). FASEB J 2008, 22:3716-3727.
27. Gohda T., Tanimoto M., Moon J.Y., et al. Increased serum endogenous secretory receptor for advanced glycation end-product (esRAGE) levels in type 2 diabetic patients with decreased renal function. Diabetes Res Clin Pract 2008, 81:196-201.
28. Yonekura H., Yamamoto Y., Sakurai S., et al. Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem J 2003, 370:1097-1109.
29. Zhang B.C., Li W.M., Xu Y.W. High-dose statin pretreatment for the prevention of contrast-induced nephropathy: a meta-analysis. Can J Cardiol 2011, 27:851-858.
30. Sarafidis P.A., Stafylas P.C., Georgianos P.I., Saratzis A.N., Lasaridis A.N. Effect of thiazolidinediones on albuminuria and proterinuria in diabetes: a meta-analysis. Am J Kidney Dis 2010, 55:835-837.
31. Cuccurullo C., Iezzi A., Fazia K.L., et al. Suppression of RAGE as a basis of simvastatin-dependent plaque stabilization in type 2 diabetes. Arterioscler Thromb Vasc Biol 2006, 26:2716-2723.
32. Lu L., Peng W.H., Wang W., Wang L.J., Chen Q.J., Shen W.F. Effects of atorvastatin on progression of diabetic nephropathy and local RAGE and soluble RAGE expressions in rats. Zhejiang Univ-Sci B 2011, 12:652-659.